European Pharma Companies Increase Shares, Votes September 2025

Several biopharmaceutical and biotech companies have announced updates to their share capital and voting rights as of September 30, 2025. AstraZeneca reported having 1,550,701,945 ordinary shares with no treasury shares, reflecting its global presence in prescription medicines across multiple therapeutic areas. Zealand Pharma disclosed a share capital increase following employee warrant exercises, emphasizing its peptide-based drug development and partnerships. Xspray Pharma increased its outstanding shares by over 4.6 million due to a rights and over-allotment issue, advancing its oncology drug candidates. EQL Pharma's share count rose due to warrant exercises, supporting its focus on niche generics in Nordic and European markets. Lastly, Ascelia Pharma's shares and votes grew following convertible conversions and a directed new issue, as it continues developing orphan oncology treatments.